5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions

5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions

Drug biotransformation and transporter kinetics dictate the magnitude, duration, and safety of pharmacotherapy. When multiple therapeutic agents are co-administered, drug-drug interactions (DDIs) can precipitate catastrophic toxicity or therapeutic failure. Clinically significant interactions are classified into pharmacokinetic interactions (where an offending drug alters the absorption, distribution, metabolism, or excretion of an object drug, changing its systemic concentration) and pharmacodynamic interactions (where drugs exert additive, synergistic, or antagonistic biological effects at target tissues without altering circulating plasma concentrations).

In Canadian pharmacy practice, identifying, intercepting, and managing drug-drug interactions is a core clinical competency evaluated on entry-to-practice examinations.

Phase I vs. Phase II Hepatic Biotransformation

Hepatic metabolism transforms lipophilic xenobiotics into hydrophilic, polar metabolites suitable for elimination in urine or bile. Hepatic biotransformation is divided into two sequential biochemical phases:

1. Phase I Functionalization Reactions

Phase I reactions introduce or unmask polar functional groups (such as $-\text{OH}$, $-\text{NH}_2$, $-\text{SH}$, or $-\text{COOH}$) on the drug molecule through:

• Oxidation: Mediated primarily by the Cytochrome P450 (CYP) monooxygenase superfamily in the smooth endoplasmic reticulum, as well as flavin-containing monooxygenases (FMO), alcohol dehydrogenase (ADH), and aldehyde dehydrogenase (ALDH).
• Reduction: Carbonyl and nitro reduction.
• Hydrolysis: Mediated by plasma and tissue esterases and amidases (e.g., cleavage of aspirin to salicylate, or remifentanil by non-specific plasma esterases).

Phase I metabolites may be pharmacologically active (e.g., diazepam metabolized to active desmethyldiazepam), toxic (e.g., acetaminophen converted via CYP2E1 to N-acetyl-p-benzoquinone imine [NAPQI]), or inactive.

2. Phase II Conjugation Reactions

Phase II reactions attach a bulky, hydrophilic endogenous molecule to a functional group on the parent drug or its Phase I metabolite:

• Glucuronidation: Mediated by uridine 5'-diphospho-glucuronosyltransferases (UGT). Glucuronidation is the most abundant Phase II pathway (e.g., morphine, lorazepam, lamotrigine, bilirubin).
• Sulfation: Mediated by sulfotransferases (SULT).
• Glutathione Conjugation: Mediated by glutathione S-transferases (GST); essential for neutralizing electrophilic toxic intermediates (such as NAPQI).
• Acetylation: Mediated by N-acetyltransferases (NAT1, NAT2); subject to genetic polymorphism ("fast" vs. "slow" acetylators affecting isoniazid and hydralazine).
• Methylation: Mediated by thiopurine S-methyltransferase (TPMT) and catechol-O-methyltransferase (COMT).

Major Cytochrome P450 Isoenzymes

The human Cytochrome P450 system encompasses dozens of distinct hemoprotein isoenzymes, but five specific isoforms account for more than $90\%$ of all clinically relevant Phase I oxidative drug metabolism: CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2.

Pharmacogenomic Pearls: Prodrug Bioactivation

Many medications are administered as biologically inactive prodrugs that mandate specific enzymatic cleavage to generate active therapeutic moieties:

1. Codeine $\xrightarrow{\text{CYP2D6}}$ Morphine: Codeine has negligible intrinsic affinity for mu-opioid receptors; its analgesic potency depends entirely on CYP2D6 O-demethylation into morphine.
   • Poor Metabolizers (PMs): Experience zero pain relief from codeine or tramadol.
   • Ultrarapid Metabolizers (UMs): Possess multiple gene copy duplications (up to $10\%\text{--}29\%$ in Middle Eastern and North African demographics). UMs rapidly convert therapeutic codeine doses into massive, lethal circulating morphine levels. Health Canada and international regulators issue strict contraindications against codeine in nursing mothers (fatal neonatal opiate toxicity via breast milk) and in pediatric post-tonsillectomy pain management.
2. Clopidogrel $\xrightarrow{\text{CYP2C19}}$ Active Thiol Metabolite: Clopidogrel requires a two-step hepatic oxidation process, with CYP2C19 playing the central rate-limiting role. Patients who are CYP2C19 Poor Metabolizers (*2/*2, *2/*3, *3/*3) cannot generate adequate active metabolite, resulting in impaired platelet inhibition and a significantly elevated risk of catastrophic stent thrombosis and recurrent myocardial infarction. Co-administration of omeprazole competitively inhibits CYP2C19 and blunts clopidogrel activation; pantoprazole has minimal CYP2C19 affinity and is the preferred PPI for gastroprotection.

Mechanisms and Time Course of Inhibition vs. Induction

Understanding the disparate kinetics of enzyme inhibition versus enzyme induction is essential for predicting when a drug-drug interaction will manifest clinically and when it will dissipate following drug discontinuation.

Enzyme Inhibition: Rapid Onset and Rapid Offset

• Mechanism: The inhibitor directly interacts with the enzyme active site (competitive inhibition), binds an allosteric regulatory site (non-competitive inhibition), or undergoes catalytic activation into a reactive intermediate that permanently inactivates the heme group (mechanism-based / suicide inhibition, e.g., clarithromycin, erythromycin, or grapefruit juice).
• Onset: Immediate and rapid. Inhibition begins as soon as the offending drug reaches the enzyme in the liver or intestinal mucosa (typically within hours to $24\text{--}48\text{ hours}$ of the first dose).
• Offset: Dissipates rapidly once the inhibitor is discontinued, governed strictly by the elimination half-life of the inhibitor (usually resolving within $3\text{ to }5$ half-lives).
• Exception: Mechanism-Based Irreversible Inhibition: When intestinal CYP3A4 is destroyed by grapefruit juice (furanocoumarins like bergamottin), normal enzymatic activity cannot return simply by clearing the juice; recovery requires de novo protein synthesis of new intestinal enterocyte enzymes, requiring $24\text{ to }72\text{ hours}$ after the last sip of juice.

Enzyme Induction: Delayed Onset and Prolonged Offset

• Mechanism: The inducer binds to intracellular nuclear receptors, notably the Pregnane X Receptor (PXR) and the Constitutive Androstane Receptor (CAR). This ligand-receptor complex translocates to the nucleus, heterodimerizes with the Retinoid X Receptor (RXR), and binds to response elements on DNA promoters, driving the transcription and translation of new CYP enzyme proteins.
• Onset: Delayed and gradual. Because induction requires de novo protein synthesis and microsomal proliferation, maximal enzyme induction requires $7\text{ to }14\text{ days}$ of continuous administration.
• Offset: Prolonged. When the inducer is discontinued, the excess enzyme molecules do not vanish immediately; they must undergo natural biological protein degradation and turnover. Inductive effects persist for $1\text{ to }3\text{ weeks}$ after stopping the offending drug.

Transporter Pharmacokinetics: P-glycoprotein (P-gp / ABCB1)

Membrane transport proteins regulate the uptake and efflux of drugs across biological barriers. The most clinically significant drug efflux pump is P-glycoprotein (P-gp), encoded by the ABCB1 gene (historically MDR1). P-gp is an ATP-dependent active efflux pump that extrudes xenobiotics out of cells, acting as a protective barrier in four strategic physiological locations:

1. Intestinal Enterocytes (Apical Brush Border): Pumps orally ingested drugs from inside enterocytes back into the gut lumen, limiting systemic bioavailability ($F$).
2. Blood-Brain Barrier (Capillary Endothelial Luminal Membrane): Pumps lipophilic xenobiotics from endothelial cells back into the capillary lumen, restricting central nervous system penetration.
3. Renal Proximal Tubular Epithelial Cells (Apical Membrane): Active secretion of drugs from tubular cells into urine, accelerating renal clearance.
4. Hepatocytes (Canalicular Membrane): Pumps drugs and metabolites into bile canaliculi, facilitating biliary excretion.

   INTESTINAL LUMEN               ENTEROCYTE CYTOPLASM            SYSTEMIC BLOOD
  ─────────────────────────────────────────────────────────────────────────────
       [ Drug ] ──────────────> [ Drug Absorbed ] ────────────> [ Systemic Circulation ]
           ▲                           │
           │                           │
           └───── [ P-gp Efflux Pump ] ┘
                   (Pumps back to lumen)

Substrate, Inhibitor, and Inducer Overlap

P-gp shares remarkable substrate and regulatory overlap with CYP3A4. Many drugs that modulate CYP3A4 simultaneously modulate P-gp:

• Narrow Therapeutic Index P-gp Substrates: Digoxin, Dabigatran etexilate, Apixaban, Rivaroxaban, Cyclosporine, Tacrolimus, Colchicine.
• Potent P-gp Inhibitors: Amiodarone, Verapamil, Diltiazem, Clarithromycin, Quinidine, Dronedarone, Itraconazole, Ritonavir.
• Potent P-gp Inducers: Rifampin, St. John's wort, Carbamazepine.

Severe Pharmacodynamic Drug Interactions

Pharmacodynamic interactions occur when two or more drugs produce synergistic or antagonistic clinical effects at target organs without altering drug blood levels.

1. Additive QT Prolongation & Torsades de Pointes (TdP)

• Mechanism: Drugs block the human ether-a-go-go-related gene (hERG) potassium channels ($I_{Kr}$ rapid delayed rectifier current), delaying cardiac ventricular repolarization, lengthening the QT interval, and precipitating polymorphic ventricular tachycardia (Torsades de Pointes).
• High-Risk Offending Drug Classes:
  • Antiarrhythmics: Class IA (Quinidine, Procainamide), Class III (Amiodarone, Sotalol, Dronedarone).
  • Antimicrobials: Fluoroquinolones (Moxifloxacin > Levofloxacin > Ciprofloxacin); Macrolides (Clarithromycin, Erythromycin, Azithromycin); Azole antifungals.
  • Psychotropics: Citalopram (maximum $20\text{ mg/day}$ in patients over 65 or with hepatic impairment), escitalopram (maximum $10\text{ mg/day}$ in the same groups); TCAs; Haloperidol (especially IV administration); Methadone.
  • Antiemetics: Ondansetron (IV doses $>16\text{ mg}$ restricted).
• Patient Risk Factors: Baseline QTc $> 450\text{ ms}$ (men) or $> 460\text{ ms}$ (women), QTc prolongation $> 500\text{ ms}$ (extreme danger threshold), hypokalemia ($< 4.0\text{ mmol/L}$), hypomagnesemia ($< 0.8\text{ mmol/L}$), bradycardia, female sex, and concurrent administration of two or more QT-prolonging agents.

2. Serotonin Syndrome (Serotonergic Toxicity)

• Mechanism: Excessive stimulation of central and peripheral $5\text{-HT}_{1A}$ and $5\text{-HT}_{2A}$ receptors.
• The Hunter Serotoxicity Criteria: Diagnosed by the presence of a serotonergic agent plus at least one of the following signs:
  1. Spontaneous clonus
  2. Inducible clonus AND agitation or diaphoresis
  3. Ocular clonus AND agitation or diaphoresis
  4. Tremor AND hyperreflexia
  5. Hypertonia AND temperature $> 38^\circ\text{C}$ AND ocular/inducible clonus
• Severe Causative Drug Combinations:
  • MAOIs (Phenelzine, Tranylcypromine, Moclobemide) + SSRIs / SNRIs / TCAs: Absolute contraindication. Requires a mandatory 14-day washout when switching between an MAOI and most antidepressants, and a 5-week washout when discontinuing Fluoxetine (due to its long-lived active metabolite, norfluoxetine, $t_{1/2} \approx 7\text{--}15\text{ days}$).
  • Linezolid (oxazolidinone antibacterial with potent, reversible non-selective MAO-A/B inhibition) + SSRIs/SNRIs.
  • Methylene Blue (potent reversible MAOI) + Serotonergic agents.
  • Opioids with Serotonergic Reuptake Inhibition: Tramadol, Tapentadol, Methadone, Meperidine, Fentanyl co-prescribed with SSRIs.
  • St. John's Wort + Serotonergic antidepressants.

3. CNS and Respiratory Depression Synergy

• Co-administration of Opioids with Benzodiazepines or Z-hypnotics (Zopiclone) triggers profound, synergistic sedation, respiratory depression, coma, and fatal overdose. Since 2018, Health Canada has required a warning sticker and a patient information handout with every dispensed opioid. Benzodiazepine monographs carry a serious warning about combining them with opioids.
• Co-administration of Opioids with Gabapentinoids (Gabapentin, Pregabalin) similarly magnifies respiratory depression risk and all-cause mortality.

4. Hemorrhagic Synergy: The "Triple Danger" on Hemostasis

• Mechanism: Combining medications that disrupt different arms of hemostasis exponentially magnifies gastrointestinal bleeding and major hemorrhages:
  1. Direct Oral Anticoagulants (DOACs) or Warfarin: Depletes fibrin clot formation.
  2. Antiplatelets (Aspirin, Clopidogrel): Inhibits primary platelet plug formation.
  3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Causes gastric mucosal ulceration via COX-1 inhibition and impairs platelet aggregation.
  4. Selective Serotonin Reuptake Inhibitors (SSRIs): Platelets do not synthesize serotonin; they rely entirely on the serotonin transporter (SERT) to absorb serotonin from plasma. SSRIs block platelet SERT, depleting intracellular serotonin stores and impairing platelet aggregation. Combining an SSRI with an NSAID or anticoagulant elevates upper gastrointestinal bleeding risk 3- to 6-fold.